Skip to main content
Contact Us
Sign Up
Subscriber Sign In
navigation
サイト内検索
COVID-19
COVID-19 Update
COVID-19 EventAnalyzer
Evaluate Vantage COVID-19 Report
COVID-19 Stories from Evaluate Vantage
Evaluate’s Business Continuity Plan
What We Do
Commercial Intelligence
Products
EvaluatePharma
EvaluatePharma Vision
Japan Drug Forecasts
European Drug Forecasts
Epi Analyzer
Evaluate Custom Solutions
Evaluate Vantage
News
Analysis
Policy & Pricing
Data Insights
Events
Medtech
Therapy Areas
Editorial Team
About Evaluate Vantage
How We Can Help You
Pharma and Biotech
Medtech
Financial Services
Management Consultancies
Service Providers
Customer Testimonials
Thought Leadership
About Us
Press Releases
Media Coverage
Executive Team
Vision & History
Careers
Current Vacancies
Contact Us
Sign Up for Evaluate Vantage
Subscriber Sign In
Search
Open configuration options
Search
Vantage
Covid-19
Covid-19 Coverage
Evaluate Vantage COVID-19 Report
News
Snippets
Deals
Trial results
Patents and litigation
Corporate strategy
Analysis
Interviews
Spotlight
Vantage points
Vantage views
Data Insights
M&A
IPO
NME approvals
Quarterly shareprice performance
Venture financing
Vantage data points
Other data
Events
Company events
Conferences
Upcoming events
Medtech
Therapy Areas
About
Editorial team
Raptor Pharmaceutical
September 20, 2016
Allergan sparks a second liver disease craze
September 14, 2016
Vitae buyout marks another comedown for exuberant biotech bulls
September 12, 2016
Raptor faces up to its new reality
August 03, 2016
Therapy focus – One step forward but two steps back in Huntington’s
April 15, 2016
Upcoming events – Phase II data for Raptor and The Medicines Company
August 13, 2015
Upcoming events: Intra-Cellular and Raptor target unmet CNS needs
August 12, 2014
Intercept soars again as safety fears fade
March 17, 2014
Raptor picks a bad week to bury bad news
February 21, 2014
Glimmers of hope in Huntington's must not be overstated
June 20, 2013
Upcoming events: Alnylam and Biogen readouts plus decision time at the CHMP meeting
May 01, 2013
After Procysbi approval the pricing battle begins
Load More
We use cookies on this website. By using this site, you agree that we may store and access cookies on your device.
Find out more.
OK
Independent, data-driven daily news and analysis on pharma, biotech and medtech.
Sign up
Latest Reports
July 29, 2020
Evaluate Vantage Pharma, Biotech & Medtech Half-Year Review 2020
April 16, 2020
Evaluate Vantage COVID-19 Report
Editor's Picks
July 07, 2020
What pandemic? Biotech floats break records
July 10, 2020
Venture investors: biotech's preppers?
June 17, 2020
Big pharma sports smallest late-stage pipeline for a decade
July 22, 2020
It’s official: “pipeline in a product” is a thing
April 22, 2020
Covid-19 antibody tests face a very specific problem
